Latest CLYM news

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Investors Business Daily · Wed, 23 Sep 2026 12:49:51 -0400

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug

MarketBeat · Thu, 03 Sep 2026 14:02:18 -0400

Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China.

Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Benzinga · Thu, 03 Sep 2026 13:52:08 -0400

Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease.

Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded

Investors Business Daily · Thu, 03 Sep 2026 09:24:03 -0400

Climb Bio reversed course Thursday despite potential "best-in-class" data for its experimental kidney disease treatment.

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

GlobeNewsWire · Thu, 03 Sep 2026 07:00:00 -0400

~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027 Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET WELLESLEY HILLS, Mass.

Climb Bio to Present at Upcoming Investor Conferences

GlobeNewsWire · Wed, 02 Sep 2026 07:00:00 -0400

WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Seeking Alpha · Thu, 23 Jul 2026 12:27:00 -0400

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Market information is provided for research and visualization and is not investment advice.